Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy-Reference-Cited by-同舟云学术

Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy

Published:2019-04 Issue:4 Volume:10 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Pfitzer Lisa,Moser Christina,Gegenfurtner Florian,Arner Anja,Foerster Florian,Atzberger Carina,Zisis Themistoklis,Kubisch-Dohmen Rebekka,Busse Johanna,Smith Rebecca,Timinszky Gyula,Kalinina Olga V.,Müller Rolf^ORCID,Wagner Ernst,Vollmar Angelika M.,Zahler Stefan^ORCID

Funder

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41419-019-1546-9.pdf

Reference45 articles.

1. Ibrahim, N. K. et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the MD Anderson experience. Cancer Chemother. Pharmacol. 43, 471–478 (1999).

2. McGowan, J. V. et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc. Drugs Ther. 31, 63–75 (2017).

3. Skladanowski, A. & Konopa, J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46, 375–382 (1993).